-
1
-
-
34848885468
-
A change in the air: smoking bans gain momentum worldwide
-
Schmidt CW. A change in the air: smoking bans gain momentum worldwide. Environ Health Perspect. 2007;115:A412-A415.
-
(2007)
Environ Health Perspect
, vol.115
, pp. A412-A415
-
-
Schmidt, C.W.1
-
2
-
-
84954550684
-
-
130521smokelesstobaccoreport.pdf. Accessed June 6, 2014
-
130521smokelesstobaccoreport.pdf. www.ftc.gov/sites/default/files/documents/reports/federal-trade-commission-smokeless-tobacco-report-2011/130521smokelesstobaccoreport.pdf. Accessed June 6, 2014.
-
-
-
-
3
-
-
61449129668
-
Is smokeless tobacco use an appropriate public health strategy for reducing societal harm from cigarette smoking?
-
Tomar SL, Fox BJ, Severson HH. Is smokeless tobacco use an appropriate public health strategy for reducing societal harm from cigarette smoking? Int J Environ Res Public Health. 2009;6:10-24. doi:10.3390/ijerph6010010.
-
(2009)
Int J Environ Res Public Health
, vol.6
, pp. 10-24
-
-
Tomar, S.L.1
Fox, B.J.2
Severson, H.H.3
-
4
-
-
33750445307
-
Public health implications of smokeless tobacco use as a harm reduction strategy
-
Savitz DA, Meyer RE, Tanzer JM, Mirvish SS, Lewin F. Public health implications of smokeless tobacco use as a harm reduction strategy. Am J Public Health. 2006;96:1934-1939. doi:10.2105/AJPH.2005.075499.
-
(2006)
Am J Public Health
, vol.96
, pp. 1934-1939
-
-
Savitz, D.A.1
Meyer, R.E.2
Tanzer, J.M.3
Mirvish, S.S.4
Lewin, F.5
-
5
-
-
34547565089
-
Should the health community promote smokeless tobacco (snus) as a harm reduction measure?
-
Gartner CE, Hall WD, Chapman S, Freeman B. Should the health community promote smokeless tobacco (snus) as a harm reduction measure? PLoS Med. 2007;4:e185. doi:10.1371/journal.pmed.0040185.
-
(2007)
PLoS Med
, vol.4
-
-
Gartner, C.E.1
Hall, W.D.2
Chapman, S.3
Freeman, B.4
-
6
-
-
84901780853
-
Smokeless tobacco use among working adults-United States, 2005 and 2010
-
Mazurek JM, Syamlal G, King BA, Castellan RM; Division of Respiratory Disease Studies, National Institute for Occupational Safety and Health, CDC. Smokeless tobacco use among working adults-United States, 2005 and 2010. MMWR Morb Mortal Wkly Rep. 2014;63:477-482.
-
(2014)
MMWR Morb Mortal Wkly Rep
, vol.63
, pp. 477-482
-
-
Mazurek, J.M.1
Syamlal, G.2
King, B.A.3
Castellan, R.M.4
-
7
-
-
79955586900
-
Global surveillance of oral tobacco products: total nicotine, unionised nicotine and tobacco-specific N-nitrosamines
-
Stanfill SB, Connolly GN, Zhang L, et al. Global surveillance of oral tobacco products: total nicotine, unionised nicotine and tobacco-specific N-nitrosamines. Tob Control. 2011;20:e2. doi:10.1136/tc.2010.037465.
-
(2011)
Tob Control
, vol.20
-
-
Stanfill, S.B.1
Connolly, G.N.2
Zhang, L.3
-
8
-
-
45849115806
-
Smokeless tobacco and cancer
-
Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. Lancet Oncol. 2008;9:667-675. doi:10.1016/S1470-2045(08)70173-6.
-
(2008)
Lancet Oncol
, vol.9
, pp. 667-675
-
-
Boffetta, P.1
Hecht, S.2
Gray, N.3
Gupta, P.4
Straif, K.5
-
9
-
-
17044407160
-
Smokeless tobacco use and risk of cancer of the pancreas and other organs
-
Boffetta P, Aagnes B, Weiderpass E, Andersen A. Smokeless tobacco use and risk of cancer of the pancreas and other organs. Int J Cancer. 2005;114:992-995. doi:10.1002/ijc.20811.
-
(2005)
Int J Cancer
, vol.114
, pp. 992-995
-
-
Boffetta, P.1
Aagnes, B.2
Weiderpass, E.3
Andersen, A.4
-
10
-
-
69949091626
-
Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis
-
Boffetta P, Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. BMJ. 2009;339:b3060.
-
(2009)
BMJ
, vol.339
-
-
Boffetta, P.1
Straif, K.2
-
11
-
-
84954476053
-
-
Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings-nsduhresults2011.pdf. Accessed June 4, 2014
-
Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings-nsduhresults2011.pdf. www.samhsa.gov/data/nsduh/2k11results/nsduhresults2011.pdf. Accessed June 4, 2014.
-
-
-
-
12
-
-
84891791619
-
Pharmacological interventions for smoking cessation: an overview and network meta-analysis
-
Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329. doi:10.1002/14651858. CD009329.pub2.
-
(2013)
Cochrane Database Syst Rev
, vol.5
-
-
Cahill, K.1
Stevens, S.2
Perera, R.3
Lancaster, T.4
-
14
-
-
83455186148
-
Pharmacological interventions for the treatment of smokeless tobacco use
-
Ebbert JO, Fagerström K-O. Pharmacological interventions for the treatment of smokeless tobacco use. CNS Drugs. 2012;26:1-10. doi:10.2165/11598450-000000000-00000.
-
(2012)
CNS Drugs
, vol.26
, pp. 1-10
-
-
Ebbert, J.O.1
Fagerström, K.-O.2
-
16
-
-
0037292527
-
Measures of abstinence in clinical trials: issues and recommendations
-
Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res. 2003;5:13-25. doi:10.1093/ntr/5.1.13.
-
(2003)
Nicotine Tob Res
, vol.5
, pp. 13-25
-
-
Hughes, J.R.1
Keely, J.P.2
Niaura, R.S.3
Ossip-Klein, D.J.4
Richmond, R.L.5
Swan, G.E.6
-
17
-
-
77957747183
-
A pilot study to assess smokeless tobacco use reduction with varenicline
-
Ebbert JO, Croghan IT, North F, Schroeder DR. A pilot study to assess smokeless tobacco use reduction with varenicline. Nicotine Tob Res. 2010;12:1037-1040. doi:10.1093/ntr/ntq134.
-
(2010)
Nicotine Tob Res
, vol.12
, pp. 1037-1040
-
-
Ebbert, J.O.1
Croghan, I.T.2
North, F.3
Schroeder, D.R.4
-
19
-
-
78650003597
-
Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial
-
Fagerström K-O, Gilljam H, Metcalfe M, Tonstad S, Messig M. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. BMJ. 2010;341:c6549.
-
(2010)
BMJ
, vol.341
-
-
Fagerström, K.-O.1
Gilljam, H.2
Metcalfe, M.3
Tonstad, S.4
Messig, M.5
-
20
-
-
80052770427
-
A pilot study of the efficacy of varenicline for the treatment of smokeless tobacco users in Midwestern United States
-
Ebbert JO, Croghan IT, Severson HH, Schroeder DR, Hays JT. A pilot study of the efficacy of varenicline for the treatment of smokeless tobacco users in Midwestern United States. Nicotine Tob Res. 2011;13:820-826. doi:10.1093/ntr/ntr078.
-
(2011)
Nicotine Tob Res
, vol.13
, pp. 820-826
-
-
Ebbert, J.O.1
Croghan, I.T.2
Severson, H.H.3
Schroeder, D.R.4
Hays, J.T.5
-
21
-
-
84892743698
-
A double-blind placebo-controlled randomized trial of varenicline for smokeless tobacco dependence in India
-
Jain R, Jhanjee S, Jain V, et al. A double-blind placebo-controlled randomized trial of varenicline for smokeless tobacco dependence in India. Nicotine Tob Res. 2014;16:50-57. doi:10.1093/ntr/ntt115.
-
(2014)
Nicotine Tob Res
, vol.16
, pp. 50-57
-
-
Jain, R.1
Jhanjee, S.2
Jain, V.3
-
22
-
-
55049140591
-
Nicotine receptor partial agonists for smoking cessation
-
Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2012;4:CD006103. doi:10.1002/14651858.CD006103.pub6.
-
(2012)
Cochrane Database Syst Rev
, vol.4
-
-
Cahill, K.1
Stead, L.F.2
Lancaster, T.3
-
23
-
-
84864360423
-
Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genes
-
Swan GE, Javitz HS, Jack LM, et al. Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genes. Pharmacogenomics J. 2012;12:349-358. doi:10.1038/tpj.2011.19.
-
(2012)
Pharmacogenomics J
, vol.12
, pp. 349-358
-
-
Swan, G.E.1
Javitz, H.S.2
Jack, L.M.3
-
24
-
-
84855875894
-
Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials
-
King DP, Paciga S, Pickering E, et al. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology. 2012;37:641-650. doi:10.1038/npp.2011.232.
-
(2012)
Neuropsychopharmacology
, vol.37
, pp. 641-650
-
-
King, D.P.1
Paciga, S.2
Pickering, E.3
-
25
-
-
33747154992
-
Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation
-
Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166:1571-1577. doi:10.1001/archinte.166.15.1571.
-
(2006)
Arch Intern Med
, vol.166
, pp. 1571-1577
-
-
Oncken, C.1
Gonzales, D.2
Nides, M.3
-
26
-
-
33745611449
-
Efficacy of varenicline, an alpha-4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial
-
Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha-4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56-63. doi:10.1001/jama.296.1.56.
-
(2006)
JAMA
, vol.296
, pp. 56-63
-
-
Jorenby, D.E.1
Hays, J.T.2
Rigotti, N.A.3
-
27
-
-
33745614361
-
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial
-
Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55. doi:10.1001/jama.296.1.47.
-
(2006)
JAMA
, vol.296
, pp. 47-55
-
-
Gonzales, D.1
Rennard, S.I.2
Nides, M.3
-
28
-
-
64849107623
-
Varenicline: a first-line treatment option for smoking cessation
-
Garrison GD, Dugan SE. Varenicline: a first-line treatment option for smoking cessation. Clin Ther. 2009;31:463-491. doi:10.1016/j. clinthera.2009.03.021.
-
(2009)
Clin Ther
, vol.31
, pp. 463-491
-
-
Garrison, G.D.1
Dugan, S.E.2
-
29
-
-
62849127996
-
Varenicline for smoking cessation: a review of the literature
-
Kaur K, Kaushal S, Chopra SC. Varenicline for smoking cessation: a review of the literature. Curr Ther Res. 2009;70:35-54. doi:10.1016/j. curtheres.2009.02.004.
-
(2009)
Curr Ther Res
, vol.70
, pp. 35-54
-
-
Kaur, K.1
Kaushal, S.2
Chopra, S.C.3
-
30
-
-
34547607413
-
A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers
-
Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther. 2007;29:1027-1039. doi:10.1016/j.clinthera.2007.06.011.
-
(2007)
Clin Ther
, vol.29
, pp. 1027-1039
-
-
Tsai, S.T.1
Cho, H.J.2
Cheng, H.S.3
-
31
-
-
33745599140
-
Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial
-
Tonstad S, Tønnesen P, Hajek P, etal. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64-71.
-
(2006)
JAMA
, vol.296
, pp. 64-71
-
-
Tonstad, S.1
Tønnesen, P.2
Hajek, P.3
-
32
-
-
74949122161
-
Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial
-
Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121:221-229. doi:10.1161/CIRCULATIONAHA.109.869008.
-
(2010)
Circulation
, vol.121
, pp. 221-229
-
-
Rigotti, N.A.1
Pipe, A.L.2
Benowitz, N.L.3
Arteaga, C.4
Garza, D.5
Tonstad, S.6
-
33
-
-
63849201453
-
Varenicline for smoking cessation: a placebo-controlled, randomized study
-
Wang C, Xiao D, Chan KPW, Pothirat C, Garza D, Davies S. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology. 2009;14:384-392. doi:10.1111/j.1440-1843.2008.01476.x.
-
(2009)
Respirology
, vol.14
, pp. 384-392
-
-
Wang, C.1
Xiao, D.2
Chan, K.P.W.3
Pothirat, C.4
Garza, D.5
Davies, S.6
-
34
-
-
84876477549
-
Effectiveness and safety of varenicline as an aid to smoking cessation: results of an inter-Asian observational study in real-world clinical practice
-
Wang C, Cho B, Xiao D, Wajsbrot D, Park PW. Effectiveness and safety of varenicline as an aid to smoking cessation: results of an inter-Asian observational study in real-world clinical practice. Int J Clin Pract. 2013;67:469-476. doi:10.1111/ijcp.12121.
-
(2013)
Int J Clin Pract
, vol.67
, pp. 469-476
-
-
Wang, C.1
Cho, B.2
Xiao, D.3
Wajsbrot, D.4
Park, P.W.5
-
35
-
-
77955634428
-
Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebocontrolled trials conducted in six Asian countries
-
Fagerström K-O, Nakamura M, Cho HJ, et al. Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebocontrolled trials conducted in six Asian countries. Curr Med Res Opin. 2010;26:2165-2173. doi:10.1185/03007995.2010.505130.
-
(2010)
Curr Med Res Opin
, vol.26
, pp. 2165-2173
-
-
Fagerström, K.-O.1
Nakamura, M.2
Cho, H.J.3
-
36
-
-
67349108044
-
Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting
-
Halperin AC, McAfee TA, Jack LM, et al. Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. J Subst Abuse Treat. 2009;36:428-434. doi:10.1016/j.jsat.2008.09.001.
-
(2009)
J Subst Abuse Treat
, vol.36
, pp. 428-434
-
-
Halperin, A.C.1
McAfee, T.A.2
Jack, L.M.3
-
38
-
-
84873089194
-
Neuropsychiatric adverse events of varenicline: a systematic review of published reports
-
Ahmed AIA, Ali ANA, Kramers C, Härmark LVD, Burger DM, Verhoeven WMA. Neuropsychiatric adverse events of varenicline: a systematic review of published reports. J Clin Psychopharmacol. 2013;33:55-62. doi:10.1097/JCP.0b013e31827c0117.
-
(2013)
J Clin Psychopharmacol
, vol.33
, pp. 55-62
-
-
Ahmed, A.I.A.1
Ali, A.N.A.2
Kramers, C.3
Härmark, L.V.D.4
Burger, D.M.5
Verhoeven, W.M.A.6
-
39
-
-
80051599762
-
Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand
-
Harrison-Woolrych M, Ashton J. Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand. Drug Saf. 2011;34:763-772. doi:10.2165/11594450-000000000-00000.
-
(2011)
Drug Saf
, vol.34
, pp. 763-772
-
-
Harrison-Woolrych, M.1
Ashton, J.2
-
40
-
-
84879947696
-
Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England
-
Buggy Y, Cornelius V, Fogg C, Kasliwal R, Layton D, Shakir SAW. Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England. Drug Saf. 2013;36:521-531. doi:10.1007/s40264-013-0046-6.
-
(2013)
Drug Saf
, vol.36
, pp. 521-531
-
-
Buggy, Y.1
Cornelius, V.2
Fogg, C.3
Kasliwal, R.4
Layton, D.5
Shakir, S.A.W.6
-
41
-
-
82855175215
-
Smoking, quitting, and psychiatric disease: a review
-
Aubin HJ, Rollema H, Svensson TH, Winterer G. Smoking, quitting, and psychiatric disease: a review. Neurosci Biobehav Rev. 2012;36:271-284. doi:10.1016/j.neubiorev.2011.06.007.
-
(2012)
Neurosci Biobehav Rev
, vol.36
, pp. 271-284
-
-
Aubin, H.J.1
Rollema, H.2
Svensson, T.H.3
Winterer, G.4
-
42
-
-
84889028067
-
Varenicline, smoking cessation, and neuropsychiatric adverse events
-
Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry. 2013;170:1460-1467.
-
(2013)
Am J Psychiatry
, vol.170
, pp. 1460-1467
-
-
Gibbons, R.D.1
Mann, J.J.2
-
43
-
-
84861412607
-
Varenicline for Smoking Cessation in Schizophrenia: safety and Effectiveness in a 12-Week Open-Label Trial
-
Pachas GN, Cather C, Pratt SI, et al. Varenicline for Smoking Cessation in Schizophrenia: safety and Effectiveness in a 12-Week Open-Label Trial. J Dual Diagn. 2012;8:117-125. doi:10.1080/15504263.2012.663675.
-
(2012)
J Dual Diagn
, vol.8
, pp. 117-125
-
-
Pachas, G.N.1
Cather, C.2
Pratt, S.I.3
-
44
-
-
84884187859
-
Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial
-
Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med. 2013;159:390-400. doi:10.7326/0003-4819-159-6-201309170-00005.
-
(2013)
Ann Intern Med
, vol.159
, pp. 390-400
-
-
Anthenelli, R.M.1
Morris, C.2
Ramey, T.S.3
-
45
-
-
84891929233
-
Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial
-
Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA. 2014;311:145-154. doi:10.1001/jama.2013.285113.
-
(2014)
JAMA
, vol.311
, pp. 145-154
-
-
Evins, A.E.1
Cather, C.2
Pratt, S.A.3
-
46
-
-
77949600076
-
Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis
-
Tonstad S, Davies S, Flammer M, Russ C, Hughes J. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf. 2010;33:289-301. doi:10.2165/11319180-000000000-00000.
-
(2010)
Drug Saf
, vol.33
, pp. 289-301
-
-
Tonstad, S.1
Davies, S.2
Flammer, M.3
Russ, C.4
Hughes, J.5
-
47
-
-
77953255862
-
Varenicline in smoking cessation
-
Tonstad S, Rollema H. Varenicline in smoking cessation. Expert Rev Respir Med. 2010;4:291-299. doi:10.1586/ers.10.27.
-
(2010)
Expert Rev Respir Med
, vol.4
, pp. 291-299
-
-
Tonstad, S.1
Rollema, H.2
-
48
-
-
84889583200
-
Reassessing the safety of varenicline
-
Evins AE. Reassessing the safety of varenicline. Am J Psychiatry. 2013;170:1385-1387.
-
(2013)
Am J Psychiatry
, vol.170
, pp. 1385-1387
-
-
Evins, A.E.1
-
49
-
-
84954520636
-
-
Accessed April 29, 2014
-
European Medicines Agency-News and Events-European Medicines Agency Confirms Positive Benefit-Risk Balance for Champix. www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/07/news_detail_001314.jsp&mid=WC0b01ac058004d5c1. Accessed April 29, 2014.
-
-
-
|